| firicabtagene autoleucel (CRG-022) / CARGO Therap |
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 123 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |
| Active, not recruiting | 1 | 52 | US | Fludarabine, Cyclophosphamide, CD22 CAR | Stanford University, National Cancer Institute (NCI) | B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B | 12/24 | 12/37 | | |
NCT06408194: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies |
|
|
| Recruiting | 1 | 20 | US | CD22CART infusion, Tisagenlecleucel, KYMRIAH | Stanford University | Leukemia, Acute Lymphoblastic Leukemia | 06/25 | 06/25 | | |
NCT04088864: CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies |
|
|
| Active, not recruiting | 1 | 10 | US | Fludarabine, Cyclophosphamide, Autologous CD22 CAR T | Stanford University | B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma | 10/23 | 09/36 | | |